2025
Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome?
Mestre-Bach G, Potenza M, Granero R, Håkansson A, Gómez-Peña M, Perales I, Vicó À, Uríszar J, Fernández-Aranda F, Sánchez I, Jiménez-Murcia S. Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome? Journal Of Behavioral Addictions 2025, 14: 465-479. PMID: 40116860, PMCID: PMC11974433, DOI: 10.1556/2006.2025.00023.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyGambling disorderPornography useEmotion regulationGD severityTreatment outcomesCognitive-behavioral therapy approachCognitive-behavioral therapy sessionsTreatment outcomes of individualsCo-occurrence of GDCo-occurrenceMental health concernsImprove treatment adherenceBehavioral addictionsTreatment dropoutOutcomes of individualsWeekly sessionsTreatment adherencePsychopathologyGamblingSessionsDisordersAssociated with higher likelihoodRelapseImpulse
2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2020
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States
Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE, Walther C, Anumudu S, Arunthamakun J, Kopecky K, Milligan G, McCullough P, Nguyen T, Shaefi S, Krajewski M, Shankar S, Pannu A, Valencia J, Waikar S, Kibbelaar Z, Athavale A, Hart P, Upadhyay S, Vohra I, Green A, Rachoin J, Schorr C, Shea L, Edmonston D, Mosher C, Shehata A, Cohen Z, Allusson V, Bambrick-Santoyo G, Bhatti N, Mehta B, Williams A, Brenner S, Walters P, Go R, Rose K, Chan L, Mathews K, Coca S, Altman D, Saha A, Soh H, Wen H, Bose S, Leven E, Wang J, Mosoyan G, Nadkarni G, Pattharanitima P, Gallagher E, Friedman A, Guirguis J, Kapoor R, Meshberger C, Kelly K, Parikh C, Garibaldi B, Corona-Villalobos C, Wen Y, Menez S, Malik R, Cervantes C, Gautam S, Mallappallil M, Ouyang J, John S, Yap E, Melaku Y, Mohamed I, Bajracharya S, Puri I, Thaxton M, Bhattacharya J, Wagner J, Boudourakis L, Nguyen H, Ahoubim A, Kashani K, Tehranian S, Thomas L, Sirganagari D, Guru P, Zhou Y, Bergl P, Rodriguez J, Shah J, Gupta M, Kumar P, Lazarous D, Kassaye S, Melamed M, Johns T, Mocerino R, Prudhvi K, Zhu D, Levy R, Azzi Y, Fisher M, Yunes M, Sedaliu K, Golestaneh L, Brogan M, Kumar N, Chang M, Thakkar J, Raichoudhury R, Athreya A, Farag M, Schenck E, Cho S, Plataki M, Alvarez-Mulett S, Gomez-Escobar L, Pan D, Lee S, Krishnan J, Whalen W, Charytan D, Macina A, Chaudhry S, Wu B, Modersitzki F, Srivastava A, Leidner A, Martinez C, Kruser J, Wunderink R, Hodakowski A, Velez J, Price-Haywood E, Matute-Trochez L, Hasty A, Mohamed M, Avasare R, Zonies D, Leaf D, Gupta S, Sise M, Newman E, Abu Omar S, Pokharel K, Sharma S, Singh H, Correa S, Shaukat T, Kamal O, Wang W, Yang H, Boateng J, Lee M, Strohbehn I, Li J, Mueller A, Redfern R, Cairl N, Naimy G, Abu-Saif A, Hall D, Bickley L, Rowan C, Madhani-Lovely F, Peev V, Reiser J, Byun J, Vissing A, Kapania E, Post Z, Patel N, Hermes J, Sutherland A, Patrawalla A, Finkel D, Danek B, Arikapudi S, Paer J, Cangialosi P, Liotta M, Radbel J, Puri S, Sunderram J, Scharf M, Ahmed A, Berim I, Vatson J, Anand S, Levitt J, Garcia P, Boyle S, Song R, Zhang J, Woo S, Deng X, Katz-Greenberg G, Senter K, Sharshir M, Rusnak V, Ali M, Bansal A, Podoll A, Chonchol M, Sharma S, Burnham E, Rashidi A, Hejal R, Judd E, Latta L, Tolwani A, Albertson T, Adams J, Reagan R, Chang S, Beutler R, Monica S, Schulze C, Macedo E, Rhee H, Liu K, Jotwani V, Koyner J, Kunczt A, Shah C, Jaikaransingh V, Toth-Manikowski S, Joo M, Lash J, Neyra J, Chaaban N, Dy R, Iardino A, Au E, Sharma J, Sosa M, Taldone S, Contreras G, De La Zerda D, Gershengorn H, Hayek S, Blakely P, Berlin H, Azam T, Shadid H, Pan M, Hayer P, Meloche C, Feroze R, Kaakati R, Perry D, Bitar A, Anderson E, Padalia K, Donnelly J, Admon A, Flythe J, Tugman M, Chang E, Brown B, Leonberg-Yoo A, Spiardi R, Miano T, Roche M, Vasquez C, Bansal A, Ernecoff N, Kapoor S, Verma S, Chen H, Kovesdy C, Molnar M, Azhar A, Hedayati S, Nadamuni M, Shastri S, Willett D, Short S, Renaghan A, Enfield K, Bhatraju P, Malik A, Semler M, Vijayan A, Joy C, Li T, Goldberg S, Kao P, Schumaker G, Goyal N, Faugno A, Schumaker G, Hsu C, Tariq A, Meyer L, Kshirsagar R, Weiner D, Jose A, Christov M, Griffiths J, Gupta S, Kapoor A, Wilson P, Arora T, Ugwuowo U. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. American Journal Of Kidney Diseases 2020, 77: 190-203.e1. PMID: 32961244, PMCID: PMC7501875, DOI: 10.1053/j.ajkd.2020.09.003.Peer-Reviewed Original ResearchConceptsPre-existing CKDChronic kidney diseaseIntensive care unitPre-existing kidney diseaseDependent chronic kidney diseaseKidney diseaseICU admissionDialysis patientsCare unitPre-existing chronic kidney diseaseSevere coronavirus disease 2019 (COVID-19) illnessCoronavirus disease 2019 illnessEffective COVID-19 therapiesIll COVID-19 patientsCOVID-19Dependent CKD patientsGray survival modelsMore dialysis patientsSevere COVID-19Acute liver injuryCOVID-19 patientsCOVID-19 therapyOutcomes of individualsCKD patientsHospital mortality
2019
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II
Inohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP, Patients and Investigators O. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal 2019, 213: 81-90. PMID: 31129441, DOI: 10.1016/j.ahj.2019.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationCardiovascular DiseasesCoronary Artery DiseaseDrug Therapy, CombinationFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeripheral Arterial DiseasePlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRegistriesStrokeTreatment OutcomeWarfarinConceptsNew-onset atrial fibrillationDirect oral anticoagulantsConcomitant antiplatelet therapyPeripheral artery diseaseAtrial fibrillationVascular diseaseAntiplatelet therapyMajor bleedingArtery diseaseMyocardial infarctionORBIT-AF II registryAtrial Fibrillation IIImproved cardiovascular outcomesVascular disease patientsProportional hazards modelOutcomes of individualsOral anticoagulationCardiovascular outcomesOral anticoagulantsTriple therapyMost patientsPatient characteristicsCoronary diseaseDual therapyNeurological events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply